Liang et al. [20] study supports our findings demonstrating the anti‐inflammatory actions of sotagliflozin, as it was shown that the use of sotagliflozin resulted in a reduction in NF‐κB levels, a notable increase in lobular and portal inflammation, and a reduction in proinflammatory cytokines such as TNF‐α and IL‐6 in the liver of the cystic fibrosis animal model. The gene discussed is NFKB1; the disease is cystic fibrosis.